Search Videos and More
News
U.S. News & World Report Recognizes Fox Chase Cancer Center Among Nation’s Best Hospitals for Cancer Care
U.S. News & World Report has ranked Fox Chase Cancer Center among the nation’s top hospitals for cancer care according to the publication’s 2026-27 Best Hospitals rankings.
News
Doximity Ask AI May Be Smart, but Trusted Answers Still Depend on Physicians Like Dr. Cohn
A longtime Doximity user, Joshua Cohn, MD, FPMRS, Associate Professor, Department of Urology, Fox Chase Cancer Center and Fox Chase – Temple Urologic Institute provider, had relied on the company’s dialer service for years.
News
Transforming Urologic Care in Philadelphia and Worldwide. The Fox Chase – Temple Urologic Institute.
In just four years, the Fox Chase – Temple Urologic Institute has leveraged the expertise of two renowned institutions to deliver an exceptionally broad range of aligned and specialized urology and urologic oncology services, led by eminent clinicians and thought leaders.
News
New Program Will Improve Patient Access to Clinical Trials
A multidisciplinary team at Fox Chase Cancer Center has developed and tested a patient-centered education program designed to reduce barriers to clinical trial participation among kidney cancer patients.
News
Combined Tests Could Reduce Unnecessary Bladder Removal
Combining a visual inspection of the bladder with a blood test to check for the presence of circulating tumor DNA can accurately predict which bladder cancer patients still have cancer in their bladder after treatment — and which do not. The findings presented today by Fox Chase Cancer Center researchers could someday help urologists identify which bladder cancer patients can safely avoid undergoing bladder removal, a risky and life-altering surgery.
News
Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according to new data presented today by Fox Chase Cancer Center researchers.
News
Researchers Find Ancestry Impacts Effectiveness of Prostate Cancer Drugs
Camille Ragin, PhD, MPH, a professor in the Cancer Prevention and Control Research Program and Associate Director for Cancer Disparities Research and Research Integration at Fox Chase Cancer Center
News
New Fox Chase Cancer Center Study Shows Partially Absorbable Mesh Significantly Lowers Parastomal Hernia Risk Following Bladder Removal
Parastomal hernia is a common complication among patients who undergo bladder removal and ileal conduit urinary diversion. Now, a new study “Very Low Rate of Parastomal Hernia Using Partially Absorbable Macroporous Mesh for Prophylactic Reinforcement in Ileal Conduit Urinary Diversion: A Collaborative Approach Between Urology and Plastic/Reconstructive Surgery,” presented by Fox Chase Cancer Center clinicians at the American Urological Association’s (AUA) 2025 Annual Meeting supports the use of partially absorbable synthetic, non-biologic parastomal mesh to significantly reduce this risk in real-world practice.
News
Adstiladrin (Nadofaragene Firadenovec-vncg): The First Intravesical Gene Therapy for Bladder Cancer Now Available at Fox Chase
Eligible patients will now have access to the first FDA-approved intravesical gene therapy for non-muscle invasive bladder cancer (NMIBC) at Fox Chase Cancer Center.
News
Meet the Navigators to Complex, Coordinated, Compassionate Genitourinary Cancer Care
A prostate, kidney, or bladder cancer diagnosis can turn someone’s world upside down. If this weren’t enough, now the patient has an additional burden of coordinating medical appointments, scheduling tests, and gathering biopsy results from other hospitals.
News
Comprehensive Cancer Care Demands Exceptional Teamwork, Collaboration and Leaders to Bring It to Life.
Centralizing scientific discovery, advanced research, and clinical care—all for a new therapeutic pathway.
News
New Fox Chase Clinical Trial Could Help Men With Intermediate-Risk Prostate Cancer Avoid Radical Treatment
Could NanoKnife be the future of prostate cancer care?